Diversify Wealth Administration LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 18.4% within the third quarter, based on its most up-to-date submitting with the Securities and Trade Fee (SEC). The institutional investor owned 11,709 shares of the corporate’s inventory after buying an extra 1,822 shares throughout the interval. Diversify Wealth Administration LLC’s holdings in Johnson & Johnson have been value $1,942,000 as of its most up-to-date SEC submitting.
Different institutional buyers have additionally just lately purchased and bought shares of the corporate. Major Line Retirement Advisors LLC lifted its stake in shares of Johnson & Johnson by 5.3% throughout the first quarter. Major Line Retirement Advisors LLC now owns 1,525 shares of the corporate’s inventory valued at $241,000 after buying an extra 77 shares throughout the interval. Iams Wealth Administration LLC lifted its place in Johnson & Johnson by 6.2% throughout the 1st quarter. Iams Wealth Administration LLC now owns 6,941 shares of the corporate’s inventory valued at $1,121,000 after buying an extra 406 shares throughout the interval. Cullinan Associates Inc. boosted its stake in shares of Johnson & Johnson by 16.0% within the 1st quarter. Cullinan Associates Inc. now owns 238,791 shares of the corporate’s inventory valued at $37,774,000 after buying an extra 32,875 shares over the past quarter. Westhampton Capital LLC grew its place in shares of Johnson & Johnson by 1.2% throughout the 1st quarter. Westhampton Capital LLC now owns 13,246 shares of the corporate’s inventory value $2,095,000 after shopping for an extra 157 shares throughout the interval. Lastly, Synergy Asset Administration LLC lifted its holdings in Johnson & Johnson by 31.6% within the first quarter. Synergy Asset Administration LLC now owns 102,669 shares of the corporate’s inventory valued at $16,241,000 after shopping for an extra 24,682 shares throughout the interval. Institutional buyers personal 69.55% of the corporate’s inventory.
Insider Transactions at Johnson & Johnson
In different Johnson & Johnson information, VP Robert J. Decker bought 5,635 shares of Johnson & Johnson inventory in a transaction on Friday, August thirtieth. The shares have been bought at a mean worth of $165.06, for a complete worth of $930,113.10. Following the sale, the vp now instantly owns 18,973 shares within the firm, valued at roughly $3,131,683.38. The commerce was a 0.00 % lower of their place. The sale was disclosed in a submitting with the Securities & Trade Fee, which is accessible via this hyperlink. 0.16% of the inventory is at the moment owned by insiders.
Wall Avenue Analysts Forecast Development
Quite a lot of analysis analysts have just lately weighed in on the corporate. Citigroup elevated their worth goal on Johnson & Johnson from $180.00 to $185.00 and gave the corporate a “purchase” ranking in a analysis word on Wednesday, October sixteenth. Morgan Stanley elevated their goal worth on Johnson & Johnson from $169.00 to $175.00 and gave the corporate an “equal weight” ranking in a analysis word on Wednesday, October sixteenth. TD Securities decreased their goal worth on Johnson & Johnson from $195.00 to $185.00 in a analysis report on Thursday, July 18th. Cantor Fitzgerald reiterated an “obese” ranking and issued a $215.00 worth goal on shares of Johnson & Johnson in a analysis report on Wednesday, October sixteenth. Lastly, Sanford C. Bernstein boosted their worth goal on shares of Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Six equities analysis analysts have rated the inventory with a maintain ranking, seven have assigned a purchase ranking and one has issued a powerful purchase ranking to the corporate. In accordance with MarketBeat, the corporate at the moment has a mean ranking of “Average Purchase” and a mean goal worth of $175.93.
View Our Newest Inventory Report on Johnson & Johnson
Johnson & Johnson Buying and selling Down 0.5 %
JNJ opened at $159.86 on Friday. The inventory has a market capitalization of $384.88 billion, a P/E ratio of 23.13, a P/E/G ratio of two.90 and a beta of 0.52. The corporate has a present ratio of 1.07, a fast ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12 month low of $143.13 and a 12 month excessive of $168.85. The agency’s fifty day easy shifting common is $163.39 and its 200 day easy shifting common is $155.35.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final issued its quarterly earnings outcomes on Tuesday, October fifteenth. The corporate reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The corporate had income of $22.47 billion for the quarter, in comparison with analyst estimates of $22.17 billion. Johnson & Johnson had a return on fairness of 35.46% and a web margin of 19.14%. The corporate’s quarterly income was up 5.2% in comparison with the identical quarter final 12 months. Throughout the identical interval within the earlier 12 months, the corporate posted $2.66 earnings per share. As a bunch, analysis analysts anticipate that Johnson & Johnson will put up 9.94 EPS for the present fiscal 12 months.
Johnson & Johnson Dividend Announcement
The agency additionally just lately disclosed a quarterly dividend, which might be paid on Tuesday, December tenth. Stockholders of report on Tuesday, November twenty sixth might be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November twenty sixth. This represents a $4.96 dividend on an annualized foundation and a dividend yield of three.10%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.
About Johnson & Johnson
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells varied merchandise within the healthcare area worldwide. The corporate’s Progressive Drugs phase gives merchandise for varied therapeutic areas, equivalent to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious ailments comprising HIV/AIDS; neuroscience, consisting of temper issues, neurodegenerative issues, and schizophrenia; oncology, equivalent to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension via retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Articles
Need to see what different hedge funds are holding JNJ? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Obtain Information & Scores for Johnson & Johnson Each day – Enter your e mail tackle under to obtain a concise day by day abstract of the newest information and analysts’ scores for Johnson & Johnson and associated firms with MarketBeat.com’s FREE day by day e mail e-newsletter.
